Practical Considerations in Selecting Therapy for Metastatic CRPC
Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.
Read More
What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?
Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
Read More
Metastatic CRPC: Practical Selection and Use of PARP Inhibitors
Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.
Read More
An Overview of PARP Inhibition in Metastatic CRPC
Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.
Read More
PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition
Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.
Read More
Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC
A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.
Read More
Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies
Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.
Read More
Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC
Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.
Read More
Addressing Unmet Needs in Nonmetastatic CRPC
Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.
Read More
Selecting Among Available AR Inhibitors in Nonmetastatic CPRC
A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.
Read More
Optimizing Management of nmCRPC: Patient Monitoring and Initiating Therapy
Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.
Read More
Clinical Scenario 2: A 64-Year-Old Man With nmCRPC
Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.
Read More
Improving Patient Monitoring in the Setting of Metastatic HSPC
Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.
Read More
Clinical Trial Data in Metastatic HSPC From the ASCO 2022 Annual Meeting
Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.
Read More
Establishing Eligibility for Frontline AR-Targeted Therapy in mHSPC
Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.
Read More
Factors in Selecting AR-Targeted Therapy for Patients With Metastatic HSPC
Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.
Read More
Optimizing Management of mHSPC: Multimodality Care and Genetic Testing
A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.
Read More
Clinical Scenario 1: A 67-Year-Old With Metastatic HSPC
Centering discussion on a clinical scenario of metastatic hormone-sensitive prostate cancer, expert panelists consider how they might approach frontline therapy in this setting.
Read More
Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology
January 8th 2021Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.
Read More
Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC
July 11th 2016Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
Read More